At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
Galcanezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Galcanezumab in Healthy Chinese Subjects
In Brief
A Phase 1 clinical trial evaluating Galcanezumab and Placebo for Healthy. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this study is to assess how fast galcanezumab gets into the blood stream and how long it takes the body to remove it. Information about side effects will be collected. The study is open to healthy Chinese participants. It will last up to about 24 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartNov 2019
Primary CompletionMay 2020
TodayJul 2026
First PostedSep 11, 2019
Enrollment StartNov 20, 2019
Primary CompletionMay 21, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.8 years ago
Interventions
Galcanezumabdrug
Administered SC
Placebodrug
Administered SC